Joseph McIntosh

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

8h-index277citations59works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(42), Chronic Lymphocytic Leukemia Research(31), CAR-T cell therapy research(22), Monoclonal and Polyclonal Antibodies Research(5), Cancer Genomics and Diagnostics(5)

Publications59 total

Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Experimental Hematology and Oncology·2026Open Access
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study
npj Precision Oncology·2025Open Access
First-in-class dual BTK-MALT1 fusion inhibitors for treating resistant Mantle Cell Lymphoma
Blood·2025
Enhancing the expansion of Naïve, potent T-cells via BTK inhibition reinvigorates CD19-CAR T-cell immunity and boosts antitumor efficacy in relapsed Mantle Cell Lymphoma
Blood·2025
BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma
Cancer Letters·2025· 2 citedOpen Access
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Blood·2025· 4 citedOpen Access
YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma
Blood Advances·2025· 2 citedOpen Access
Abstract 3811: Drug discovery of potent and specific CDK9 protein degraders for the treatment of refractory lymphomas
Cancer Research·2025
YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma
2025· 1 citedOpen Access
<i>Orally Effective CDK9 Inhibitor YX0798 for Treating Aggressive Lymphoma</i>
Blood·2024
Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma
Nature Communications·2024Open Access
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
Biomarker Research·2024· 7 citedOpen Access
Analogs of α-conotoxin PnIC are selective for α7β2 over α7-only subtype nicotinic acetylcholine receptors
Journal of Pharmacology and Experimental Therapeutics·2024
Abstract 676: The integrated stress activator BTM-3566 overcomes therapeutic resistance in mantle cell lymphoma
Cancer Research·2024
Abstract 602: Targeting CDK9 with a novel potent and selective inhibitor, YX0798, in CAR-T-relapsed mantle cell lymphoma models
Cancer Research·2024
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Experimental Hematology and Oncology·2024· 22 citedOpen Access
The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma
Blood·2023· 3 cited
Dual Targeting of ROR1 and BTK Augments the Anti-Lymphoma Activity in Mantle Cell Lymphoma
Blood·2023
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
Cell Death and Disease·2023· 8 citedOpen Access
The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma
Blood·2023· 4 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Michael Wang(45), Changying Jiang(32), Yang Liu(27), Alexa A Jordan(24), Yuxuan Che(22), Yixin Yao(21), Qingsong Cai(19), Angela Leeming(15), Fangfang Yan(14), Yijing Li(13), Heng‐Huan Lee(13), Jovanny Vargas(12), Yijing Li(11), Wei Wang(11), Preetesh Jain(10), Yang Liu(10), Changying Jiang(10), Tianci Zhang(10), Linghua Wang(9), Jingling Jin(9)